Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease-Reference-Cited by-同舟云学术

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease

Published:2006-04-11 Issue:10 Volume:113 Page:1441-1448
ISSN:0300-9564
Container-title:Journal of Neural Transmission
language:en
Short-container-title:J Neural Transm

Author:

Müller T.,Erdmann C.,Muhlack S.,Bremen D.,Przuntek H.,Goetze O.,Woitalla D.

Publisher

Springer Science and Business Media LLC

Subject

Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00702-006-0442-5.pdf

Reference22 articles.

1. LEVODOPA AND 3-O-METHYLDOPA IN CEREBROSPINAL FLUID AFTER LEVODOPA-CARBIDOPA ASSOCIATION

2. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient

3. Levodopa and the Progression of Parkinson's Disease

4. Standardized training tools for the UPDRS activities of daily living scale: Newly available teaching program

5. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations;Journal of Neural Transmission;2023-08-21

2. Betaine—The dark knight of the brain;Basic & Clinical Pharmacology & Toxicology;2023-02-09

3. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients;Cells;2022-04-30

4. GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease;Neurodegenerative Disease Management;2022-02

5. Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease;NeuroPsychopharmacotherapy;2022